CorMedix Inc.CRMDNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

CorMedix CEO touts Melinta pivot, DefenCath TDAPA transition and Q2 REZZAYO Phase 3 data at Leerink

CorMedix (NASDAQ: CRMD) Chief Executive Officer Joseph Todisco told attendees at the Leerink Global Healthcare Conference that the company has undergone a significant shift over the last year, moving from what he described as a "single product company" to a diversified specialty pharmaceutical business focused on institutional settings of care following its 2025 acquisition of Melinta.

defenseworld.net

CorMedix Touts Q2 REZZAYO Data, Melinta Integration and DefenCath Reimbursement Shift at Conference

CorMedix (NASDAQ: CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company's focus on expanding its pipeline while integrating the recently acquired Melinta Therapeutics assets and navigating evolving reimbursement dynamics for its catheter lock solution DefenCath. Company overview and pipeline priorities Chief Executive Officer Joe Todisco described CorMedix as a specialty

defenseworld.net

CorMedix Q4 Earnings Call Highlights

CorMedix (NASDAQ: CRMD) executives said 2025 was a "transformational" year, highlighted by DefenCath reaching peak sales of "just under $260 million," the acquisition of Melinta Therapeutics, and the completion of targeted cost synergies by the fourth quarter. On the company's fourth-quarter and full-year 2025 earnings call, management also reiterated its outlook for 2026 and provided initial

seekingalpha.com

CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript

zacks.com

CorMedix (CRMD) Lags Q4 Earnings Estimates

CorMedix (CRMD) came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.22 per share a year ago.

globenewswire.com

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.

globenewswire.com

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time.

zacks.com

CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

zacks.com

Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?

CorMedix heads into Q4 earnings with DefenCath sales, Melinta product contributions, and its muted 2026 guidance firmly in focus.

defenseworld.net

Principal Financial Group Inc. Invests $1.01 Million in CorMedix Inc $CRMD

Principal Financial Group Inc. bought a new stake in shares of CorMedix Inc (NASDAQ: CRMD) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 86,437 shares of the company's stock, valued at approximately $1,005,000. Principal Financial Group Inc. owned about 0.11% of CorMedix at the

zacks.com

CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?

CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.

seekingalpha.com

CorMedix Inc. (CRMD) Analyst/Investor Day Transcript

globenewswire.com

CorMedix to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March.

zacks.com

CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside

CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.

defenseworld.net

CorMedix (NASDAQ:CRMD) to Buyback $75.00 million in Outstanding Stock

CorMedix (NASDAQ: CRMD - Get Free Report) declared that its board has initiated a stock repurchase plan on Monday, February 2nd, RTT News reports. The company plans to repurchase $75.00 million in shares. This repurchase authorization permits the company to repurchase up to 12.3% of its stock through open market purchases. Stock repurchase plans are generally

globenewswire.com

CorMedix Therapeutics Announces Share Repurchase Program

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock.

zacks.com

CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?

CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.

globenewswire.com

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will host an in-person and virtual analyst day in New York on Tuesday, February 10, 2026 with presentations and panels from 1:00 PM to 3:00 PM Eastern.

defenseworld.net

Hussman Strategic Advisors Inc. Purchases 252,000 Shares of CorMedix Inc $CRMD

Hussman Strategic Advisors Inc. increased its position in CorMedix Inc (NASDAQ: CRMD) by 400.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 315,000 shares of the company's stock after purchasing an additional 252,000 shares during the quarter. CorMedix makes up 0.8%

zacks.com

Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?

CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance